GUANGZHOU, China--(BUSINESS WIRE)--Guangzhou Bio-Gene, a clinical-stage biopharmaceutical company developing a pipeline of innovative oncology therapies, today announced the company will present at the 2021 American Society of Clinical Oncology ("ASCO") Annual Meeting taking place June 4-8^th, 2021.

The presentation, entitled �The efficacy and safety of anti-CLL1 based CAR-T cells in children with relapsed or refractory acute myeloid leukemia: a multi-center interim analysis� will highlight Phase I clinical data demonstrating the safety and efficacy of BG1805, a potent anti-CLL1 CAR-T therapy, in R/R AML pediatric patients. An abstract of the presentation is currently available on ASCO website (https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.10000).

Presentation details are as follows:

About Guangzhou Bio-Gene

Guangzhou Bio-Gene is a clinical-stage biopharmaceutical company focused on innovative oncology therapeutics. Bio-Gene is developing a pipeline of autologous and allogeneic CAR-T therapies for the treatment of a broad range of cancers and other diseases. The company is headquartered in Guangzhou, China.

Contacts

Guangzhou Bio-Gene
Guangchao Li, PhD
Senior Director, Business Development

[email protected]
www.gzbiogene.com